Oncology Medical News about Soft Tissue Sarcomas

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Recommendations on the use of 18F-FDG PET in oncology

3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials

4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Early outcomes of soft tissue sarcomas presenting with metastases and treated with chemotherapy
American Journal of Clinical Oncology, 06/08/09

King JJ et al. – Study reports that soft tissue sarcoma patients presenting with metastatic disease have a low survival rate, but complete eradication of tumor with chemotherapy correlated with longer survival.

Methods

Aim was to describe the outcomes for pts with metastatic soft tissue sarcoma treated with chemotherapy
A retrospective review of the records of 383 soft tissue sarcoma pts treated from 1997 to 2006
35 pts met the inclusion criteria-metastatic disease on presentation:
- primary tumor outside the abdomen
- treatment with chemotherapy; and
- minimum follow-up of 3 months
Treatments were individualized and determined by a multidisciplinary oncology team
Patient survival was calculated from the diagnostic biopsy to the date of death or last f/u

Results

Mean age was 47 yrs; most common tumors involved were MFH and leiomyosarcoma
16/35 (46%) pts had died at last follow-up
Mean patient survival was 24 mo; 2-yr and 5-yr survival rates were 64% and 24%, respectively
29 pts (83%) presented with pulmonary metastasis, 6 with bone metastases (17%), 4 with regional node metastases (11%), and 4 with soft tissue metastases (11%)
Survival was the same for those with pulmonary and only extrapulmonary metastases
The 10 pts with complete resection or complete chemotherapy response of all detectable lesions had longer mean survival (34 mo) vs 25 pts who had partial/no resection or response (20 mo)

<< Previous
Proton therapy for maxillary sinus carcinoma

Next >>
Paraganglioma of the head and neck: Long-term local control with...